


# Structure-based Drug Design

Sergei Evteev  
Lead Scientist  
FSUE VNIIA


Fall into ML 2024




# The Landscape of AI-discovered Drug Candidates and Targets


The indicated data are for 2023

Legend		
Target Novelty	Low	Moderate High
Pipeline	Active	molecule failed or discontinued







Model preparation



Binding site identification



Hot spots identification



*de novo* generation

## AlphaFold for a medicinal chemist: tool or toy?

Ya. A. Ivanenkov<sup>ab</sup>, S. A. Evteev<sup>ab</sup>, A. S. Malyshev<sup>ab</sup>, V. A. Terentiev<sup>ab</sup>, D. S. Bezrukov<sup>c</sup>, A. V. Ereshchenko<sup>ab</sup>, A. A. Korzhenevskaya<sup>a</sup>, B. A. Zagribelnyy<sup>c</sup>, P. V. Shegai<sup>a</sup>, A. D. Kaprin<sup>da</sup>


<sup>a</sup> *P.Hertsen Moscow Oncology Research Institute, Moscow, Russian Federation*


<sup>b</sup> *Dukhov Automatics Research Institute (VNIIA), Moscow, Russian Federation*

<sup>c</sup> *Department of Chemistry, Lomonosov Moscow State University, Moscow, Russian Federation*






<sup>d</sup> *Peoples' Friendship University of Russia (RUDN), Moscow, Russian Federation*


English full-text

DOI: <https://doi.org/10.59761/RCR5107> 














# AlphaFold Optimizer






- Virtual screening was performed using both original and optimized AlphaFold models
- Among 39 compounds tested, 10 hits were found
- All 10 hits were detected using optimized model while only 7 of them were detected using original AlphaFold structure


Compound ID	Structure	Inhibition, %	Predicted initial model	by	Predicted refined model
1		94	+		+
2		84	-		+
3		93	+		+
4		92	-		+
5		86	+		+
6		84	+		+
7		100	+		+
8		51	-		+
9		54	+		+
10		70	+		+




Model preparation



Binding site identification



Hot spots identification



*de novo* generation



Journal of Chemical Information and Modeling > Vol 63/Issue 4 > Article



Cite



Share



Jump to



Expand

MACHINE LEARNING AND DEEP LEARNING | February 6, 2023

# SiteRadar: Utilizing Graph Machine Learning for Precise Mapping of Protein–Ligand-Binding Sites

Sergei A. Evteev\*, Alexey V. Ereshchenko, and Yan A. Ivanenkov



Access Through Your Institution


Other Access Options





Supporting Information (1)

## Abstract


Identifying ligand-binding sites on the protein surface is a crucial step in the structure-based drug design. Although multiple techniques have been proposed, including those using machine learning algorithms, the existing solutions do not provide significant advantages over nonmachine learning approaches and there is still a big room for improvement. The low ability to identify protein–ligand-binding sites makes available approaches inapplicable to automated drug design. Here, we present SiteRadar, a new algorithm for mapping cavities that are likely to bind a small-molecule ligand. SiteRadar shows higher accuracy in binding site identification compared with FPocket and PURESNet. SiteRadar demonstrates an ability to detect up to 74% of true ligand-binding sites according to the top N + 2 metric and usually covers approximately 80% of ligand atoms. Therefore, SiteRadar can be regarded as a promising solution for implementation into algorithms for automated drug design.



# Graph-based approach




# SiteRadar Pipeline




## Case studies


Allosteric binding site



Site for covalent ligand binding




Solvent-exposed binding site



a - AA specific



Protein-protein interaction




b - Geometric




# *in silico* validation




0 – Nucleic acids  
 1 – Carbohydrates  
 2 – Heme  
 3 – Nucleotides / ATP  
 4 – Peptides  
 5 – Undefined




Model preparation



Binding site identification




Hot spots identification



*de novo* generation


# SiteMap


Utilizes traditional docking, diffusion and positional filters




Scaffolds Selected 0 / 3

ID	SMILES	Docking score	
<input type="checkbox"/> Mol-0.1	c1ccncc1	-3.95	
<input type="checkbox"/> Mol-0.2	c1ccncc1	-3.70	
<input type="checkbox"/> Mol-0.3	c1ccncc1	-3.69	







Model preparation



Binding site identification



Hot spots identification



*de novo* generation



ACS Medicinal Chemistry Letters > Vol 14/Issue 7 > Article

Open Access

MICROPERSPECTIVES | June 29, 2023

# The Hitchhiker's Guide to Deep Learning Driven Generative Chemistry

Yan Ivanenkov, Bogdan Zagribelnyy, Alex Malyshev, Sergei Evteev, Victor Terentiev, Petrina Kamy, Dmitry Bezrukov, Alex Aliper, Feng Ren, and Alex Zhavoronkov\*

Open PDF



Cite



Share



Jump to



Expand

## Abstract

This microperspective covers the most recent research outcomes of artificial intelligence (AI) generated molecular structures from the point of view of the medicinal chemist. The main focus is on studies that include synthesis and experimental *in vitro* validation in biochemical assays of the generated molecular structures, where we analyze the reported structures' relevance in modern medicinal chemistry and their novelty. The authors believe that this review would be appreciated by medicinal chemistry and AI-driven drug design (AIDD) communities and can be adopted as a comprehensive approach for qualifying different research outcomes in AIDD.

This publication is licensed under [CC-BY-NC-ND 4.0](#).



Copyright © 2023 The Authors. Published by American Chemical Society



Get e-Alerts

ACS Medicinal Chemistry Letters

Cite this: ACS Med. Chem. Lett. 2023, 14, 7, 901–915

<https://doi.org/10.1021/acsmedchemlett.3c00041>

Published June 29, 2023

Copyright © 2023 The Authors. Published by American Chemical Society. This publication is licensed under [CC-BY-NC-ND 4.0](#).

Article Views

15k

Altmetric

24

Citations

4

[Learn about these metrics](#)

## Recommended Articles

Chemistry42: An AI-Driven Platform for Molecular Design and Optimization






February 2, 2023 | [Journal of Chemical Information and Modeling](#)






Yan A. Ivanenkov, Daniil Polykovskiy, Dmitry Bezrukov, Bogdan Zagribelnyy, ...





Generative Models as an Emerging Paradigm in the Chemical Sciences

April 13, 2023 | [Journal of the American Chemical Society](#)

# Quantum-assisted fragment-based automated structure generator (QFASG) for small molecule design: an *in vitro* study

 Sergei Evteev<sup>1\*</sup>
 Yan Ivanenkov<sup>1</sup>
 Ivan Semenov<sup>1</sup>
 Maxim Malkov<sup>2</sup>
 Olga Mazaleva<sup>1</sup>




 Artem Bodunov<sup>1</sup>
 Dmitry Bezrukov<sup>2</sup>
 Denis Sidorenko<sup>1</sup>
 Victor Terentiev<sup>1</sup>
 Alex Malyshev<sup>1</sup>

 Bogdan Zagribelnyy<sup>2</sup>
 Anastasia Korzhenevskaya<sup>1</sup>
 Alex Aliper<sup>2</sup>
 Alex Zhavoronkov<sup>2</sup>

<sup>1</sup> Insilico Medicine Hong Kong Ltd., Hong Kong, Hong Kong SAR, China


<sup>2</sup> Insilico Medicine AI Limited, Abu Dhabi, United Arab Emirates

## Target Protein




# NATURE-BASED GENERATOR (NBG)

Atom-wise Generation of Ligand Structures Complementary to Macromolecular Environment




# Structure generation

Known crystals reproduction




Heat shock protein 90-α  
PDB ID 5J82




Phosphatase SHP2  
PDB ID 7JVM

# Structure generation


Design of new compounds



JAK1  
PDB ID 6ELR



PARP1  
PDB ID 4ZZZ



SARS Cov2 main protease  
PDB ID 8UR9



**Presude**  
Lifesciences

**Target X (Presude Lifesciences)**

- Hit compound with  $IC_{50} = 3\mu M$  was obtained

# Thank you

Sergei Evteev  
[saevteev@vniia.ru](mailto:saevteev@vniia.ru)



@SERGEI\_EVTEEV

